http://www.trendsinurology.com Trends news RSS Feed http://www.trendsinurology.com/details/news/1455405/Tivozanib_superior_to_sorafenib_in_renal_cell_cancer.html Preliminary analysis of the TIVO-1 trial has shown that the new antivascular endothelial growth factor inhibitor tivozanib increases progression-free survival (PFS) significantly more than the multikinase inhibitor sorafenib in patients with advanced renal cell cancer.   2012-01-30T14:16:00Z http://www.trendsinurology.com/details/news/1455403/NICE_set_against_cabazitaxel.html NICE looks set to adhere to its preliminary decision not to recommend cabazitaxel (Jevtana) as second-line therapy for hormone-refractory metastatic prostate cancer after failure of docetaxel-based chemotherapy.   2012-01-30T14:15:00Z http://www.trendsinurology.com/details/news/1455401/Rare_genetic_link_for_prostate_cancer.html US scientists have identified a rare gene mutation strongly associated with the risk of developing prostate cancer (NEJM 2012;366:141–9).   2012-01-30T14:14:00Z http://www.trendsinurology.com/details/news/1451665/Etravirine_now_in_200mg_tablets.html The antiretroviral etravirine (Intelence) is now available as 200mg tablets. (It was previously formulated only as 100mg tablets.) Manufacturer Janssen says the new tablet strength will reduce the pill burden from four to two per day. Both strengths can be taken dispersed in a glass of water.   2012-01-24T14:22:00Z http://www.trendsinurology.com/details/news/1451663/Prostate_cancer_biomarker_evidence_retracted.html The journal Urology has retracted the paper that provided key evidence that early prostate cancer antigen-2 (EPAC-2) is a reliable biomarker.   2012-01-24T14:14:00Z